Aurobindo Pharma has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Ravicti Oral Liquid of Horizon Therapeutics U.S. Holding LLC.

Market Opportunity and Product Details

The newly approved Glycerol Phenylbutyrate Oral Liquid represents a significant commercial opportunity in the US pharmaceutical market. The product targets a substantial market segment with specific therapeutic applications.

Therapeutic Application and Manufacturing

Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and amino acid supplementation alone. This specialized therapeutic application addresses a critical medical need in the treatment of rare metabolic disorders.

The company will manufacture the approved product at its Unit-III facility and plans an immediate launch in the US market. This rapid market entry strategy demonstrates Aurobindo Pharma's manufacturing readiness and regulatory compliance capabilities.

Regulatory Portfolio Expansion

With this latest approval, Aurobindo Pharma now holds a total of 579 ANDA approvals from the USFDA, comprising 556 final approvals and 23 tentative approvals. This milestone reinforces the company's strong regulatory track record and ability to navigate complex approval processes.

Strategic Significance

This USFDA approval strengthens Aurobindo Pharma's presence in the US pharmaceutical market and expands its product portfolio in specialized therapeutic areas. The approval demonstrates the company's continued focus on developing niche pharmaceutical products that address specific medical conditions and represent meaningful commercial opportunities in the global healthcare market.

Aurobindo Pharma 's biologics subsidiary TheraNym Biologics has announced the execution of an additional product schedule with Merck Sharp & Dohme Singapore Trading Pte. Ltd. (MSD), further expanding their existing contract manufacturing relationship. The development involves a significant greenfield manufacturing facility investment as disclosed under SEBI regulations.

Macquarie's Investment Outlook

Macquarie has maintained its Underperform rating on Aurobindo Pharma with a target price of ₹1,050. While the expanded biologics manufacturing deal with Merck validates the company's biologics capabilities, analysts expect meaningful financial upside only in 3-4 years as the facility ramps up operations.

Enhanced Partnership with Merck Sharp & Dohme

TheraNym Biologics has strengthened its collaboration with MSD by executing an additional product schedule that expands the existing CMO agreement initiated in May 2024. This latest development serves to further broaden the scope of their strategic partnership in biologics manufacturing.

Major Manufacturing Investment - Unit 2

Under the newly signed product schedule, TheraNym Biologics will construct a greenfield project for commissioning a large scale mammalian Drug Substance manufacturing facility designated as "Unit 2". The facility will house substantial bioreactor capacity with requisite downstream purification infrastructure.

Regulatory Compliance and Business Rationale

The company has made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the regulatory filing, TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement. The initiative aims to further expand the existing relationship in contract manufacturing operations for biologicals, strengthening the company's position in the growing biologics manufacturing sector.